Multiple Myeloma Treatment Market Research Report - Global Forecast till 2027

Multiple Myeloma Treatment Market Trends, Insights and Size Analysis By Treatment (Chemotherapy, Radiation Therapy, Stem Cell Transplant, Corticosteroids, Interferon, and Others), End User (Hospitals, Clinics, Independent Pharmacies, and Others)—Forecast till 2027

ID: MRFR/Pharma/5354-HCR | February 2021 | Region: Global | 90 pages

Multiple Myeloma Treatment Market Scenario:


The multiple myeloma treatment market is expected to rise steadily at a CAGR of 11.0% during the forecast period from 2018–2023.


Multiple myeloma is a cancer of plasma cells. Plasma cells are found in the bone marrow and are an important part of the immune system. The immune system is made up of several types of cells which includes T cells and B cells that work together to fight against infections and other diseases. Lymphocytes are one of the important types of white blood cells (WBCs) in the immune system. Different types of lymphocytes are present in many areas of the body, such as lymph nodes, the bone marrow, the intestines, and the bloodstream.


The multiple myeloma treatment market is anticipated to grow by an increase in aging population, increase in healthcare expenditure, and increasing use of novel cancer drugs in the market, whereas increasing prevalence of disease along with growing elderly population is the prime factor to drive the growth of this market during the forecast period. It has also been observed that the upcoming drug pipeline of multiple myeloma is promising. Other factors such as biological drugs and stem cell therapies are expected to drive the market in the future. The key players in the multiple myeloma treatment market are accelerating the research and development activities for multiple myeloma treatment. In 2018, drugs therapy is expected to be the largest market due to key driving factors such as rising demand for non-invasive treatments, and incessant development in research and development activities. 


Despite the drivers, factors such as the high cost of treatment and limited target patient population may hinder the growth of the multiple myeloma treatment market.


Key players:


Some of the key players in the multiple myeloma treatment market are



  • Celgene Corporation

  • Janssen Biotech, Inc.

  • Bristol-Myers Squibb Company

  • Novartis AG

  • Millennium Pharmaceuticals

  • Amgen, Inc.

  • Genzyme Corporation

  • Juno Therapeutics

  • Johnson & Johnson

  • Hoffmann-La Roche Ltd.

  • GlaxoSmithKline plc

  • AbbVie Inc.

  • Novartis AG

  • Innate Pharma SA

  • Celldex Therapeutics, Inc.

  • Onyx Pharmaceuticals

  • Pfizer

  • Takeda Pharmaceuticals


Market Segmentation:


The market of multiple myeloma treatment is further segmented into treatment types and end-users. Based on treatment types the market is segmented into chemotherapy, corticosteroids, interferon, stem cell transplant, and radiation therapy. Chemotherapy is further sub-segmented into bendamustine (treanda), cyclophosphamide (Cytoxan), doxorubicin (adriamycin), etoposide (vp-16), liposomal doxorubicin (Doxil), melphalan (Alkeran, evomela), vincristine (Oncovin). On the basis of end-user global multiple myeloma treatment market is further segmented into hospitals, clinics, rehabilitative center treatment, independent pharmacies, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The multiple myeloma treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of market.   


The European multiple myeloma treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The multiple myeloma treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Geographically, North America is expected to hold the largest share in global multiple myeloma treatment market due to key driving factors such as rising prevalence of multiple myeloma, high awareness associated with early cancer diagnosis and treatment, supportive reimbursement policies, and developed healthcare infrastructure. 


Europe has been dominating the multiple myeloma treatment market owing to the faster approval rates and favorable healthcare policies and the presence of major players in this region. Higher prevalence of multiple myeloma in developed economies is driving the growth of the Europe market. 


Asia-Pacific is expected to show exponential growth due to rising awareness associated with cancer diagnosis and developing healthcare infrastructure is responsible for high accessibility to modern technology.


Furthermore, factors such as increased healthcare infrastructure and improved healthcare reimbursement policies are responsible for the growth of multiple myeloma treatment market in the Middle East and Africa.


Global Multiple Myeloma Treatment Market Share (%), by Region, 2017  


Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American Association of the neurological surgeon

Segmentation


The Market of Multiple Myeloma Treatment, by Treatment



  • Chemotherapy 

  • Bendamustine (Treanda)

  • Cyclophosphamide (Cytoxan)

  • Doxorubicin (Adriamycin)

  • Etoposide

  • Liposomal doxorubicin (Doxil)

  • Melphalan (Alkeran, Evomela)

  • Vincristine (Oncovin)

  • Corticosteroids

  • Interferon

  • Stem Cell Transplant

  • Radiation Therapy


The Market of Multiple Myeloma Treatment, by End User



  • Hospitals

  • Clinics

  • Independent pharmacies

  • Others


The Market of Multiple Myeloma Treatment, by Region



  • Americas


    • North America


      • US

      • Canada


    • South America


  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe


  • Asia Pacific


    • Japan

    • China

    • India

    • Australia

    • Republic of Korea

    • Rest of Asia Pacific


  • Middle East & Africa


    • Middle East

    • Africa



Intended Audience



  • Manufacturers and Suppliers

  • Hospitals and clinics

  • Laboratories and Associations

  • Research institutes



Report Scope:
Report Attribute/Metric Details
  Market Size    2027: Significant Value
  CAGR   11.0% (2018 - 2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Treatment, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Janssen Biotech, Inc., Bristol-Myers Squibb Company, Takeda Pharmaceuticals Millennium Pharmaceuticals, Novartis AG, Genzyme Corporation, Juno Therapeutics, Johnson & Johnson, Novartis AG, Celgene Corporation, AbbVie Inc., Amgen, Inc., Innate Pharma SA, Celldex Therapeutics, Inc., GlaxoSmithKline plc, Pfizer, F. Hoffmann-La Roche Ltd., Onyx Pharmaceuticals
  Key Market Opportunities   Rising demand for non-invasive treatments, and incessant development in research and development activities.
  Key Market Drivers

  • Rise in healthcare expenditure
  • Growing elderly population
  • High awareness about early cancer diagnosis and treatment


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    The multiple myeloma treatment market is projected to grow at an 11.0% CAGR between 2020-2027.

    North America is projected to command the largest share in the multiple myeloma treatment market.

    Rise in healthcare expenditure and growing elderly population is boosting market growth.

    High treatment cost may limit the multiple myeloma treatment market growth.

    Different end use industries of the multiple myeloma treatment market include independent pharmacies, hospitals, clinics, and others.

    Table of Contents:

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Multiple Myeloma Treatment Market, by Treatment

    6.1 Introduction

    6.2 Chemotherapy

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.2.1 Bendamustine (Treanda)

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.2.2 Cyclophosphamide (Cytoxan)

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.2.3 Doxorubicin (Adriamycin)

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.2.4 Etoposide

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.2.5 Liposomal doxorubicin (Doxil)

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.2.6 Melphalan (Alkeran, Evomela)

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.2.7 Vincristine (Oncovin)

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3 Corticosteroids

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.4 Interferon

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.5 Stem Cell Transplant

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.6 Radiation therapy

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 7. Global Multiple Myeloma Treatment Market, by End-User

    7.1 Introduction

    7.2 Hospitals

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.3 Clinics

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.4 Independent Pharmacies

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.5 Other

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 8. Global Multiple Myeloma Treatment Market, by Region

    8.1 Introduction

    8.2 Americas

    8.2.1 North America

    8.2.1.1 US

    8.2.1.2 Canada

    8.2.2 South America

    8.3 Europe

    8.3.1 Western Europe

    8.3.1.1 Germany

    8.3.1.2 France

    8.3.1.3 Italy

    8.3.1.4 Spain

    8.3.1.5 UK

    8.3.1.6 Rest of Western Europe

    8.3.2 Eastern Europe

    8.4 Asia-Pacific

    8.4.1 Japan

    8.4.2 China

    8.4.3 India

    8.4.4 Australia

    8.4.5 South Korea

    8.4.6 Rest of Asia-Pacific

    8.5 Middle East & Africa

    8.5.1 Middle East

    8.5.2 Africa

    Chapter 9 Company Landscape


    9.1 Introduction

    9.2 Market Share Analysis

    9.3 Key Development & Strategies


    Chapter 10. Company Profiles


    10.1 Celgene Corporation

    10.1.1 Company Overview

    10.1.2 Product Overview

    10.1.3 Financials Overview

    10.1.4 Key Developments

    10.1.5 SWOT Analysis

    10.2 Janssen Biotech, Inc.

    10.2.1 Company Overview

    10.2.2 Product Overview

    10.2.3 Financial Overview

    10.2.4 Key Developments

    10.2.5 SWOT Analysis

    10.3 Bristol-Myers Squibb Company

    10.3.1 Company Overview

    10.3.2 Product Overview

    10.3.3 Financial Overview

    10.3.4 Key Development

    10.3.5 SWOT Analysis

    10.4 Novartis AG

    10.4.1 Company Overview

    10.4.2 Product Overview

    10.4.3 Financial Overview

    10.4.4 Key Development

    10.4.5 SWOT Analysis

    10.5 Millennium Pharmaceuticals

    10.5.1 Company Overview

    10.5.2 Product Overview

    10.5.3 Financial overview

    10.5.4 Key Developments

    10.5.5 SWOT Analysis

    10.6 Amgen, Inc

    10.6.1 Company Overview

    10.6.2 Product Overview

    10.6.3 Financial Overview

    10.6.4 Key Developments

    10.6.5 SWOT Analysis

    10.7 Genzyme Corporation

    10.7.1 Overview

    10.7.2 Product Overview

    10.7.3 Financial Overview

    10.7.4 Key Developments

    10.7.5 SWOT Analysis

    10.8 Juno Therapeutics

    10.8.1 Overview

    10.8.2 Product Overview

    10.8.3 Financials

    10.8.4 Key Developments

    10.8.5 SWOT Analysis

    10.7 Johnson & Johnson

    10.7.1 Overview

    10.7.2 Product Overview

    10.7.3 Financials

    10.7.4 Key Developments

    10.7.5 SWOT Analysis

    10.8 F. Hoffmann-La Roche Ltd

    10.8.1 Overview

    10.8.2 Product Overview

    10.8.3 Financials

    10.8.4 Key Developments

    10.8.5 SWOT Analysis

    10.11 GlaxoSmithKline plc

    10.91 Overview

    10.92 Product Overview

    10.93 Financials

    10.94 Key Developments

    10.95 SWOT Analysis

    10.10 AbbVie Inc

    10.10.1 Overview

    10.10.2 Product Overview

    10.10.3 Financials

    10.10.4 Key Developments

    10.10.5 SWOT Analysis

    10.13 Innate Pharma SA

    10.13.1 Overview

    10.13.2 Product Overview

    10.13.3 Financials

    10.13.4 Key Developments

    10.13.5 SWOT Analysis

    10.14 Celldex Therapeutics, Inc

    10.14.1 Overview

    10.14.2 Product Overview

    10.14.3 Financials

    10.14.4 Key Developments

    10.14.5 SWOT Analysis

    10.15 Onyx Pharmaceuticals

    10.15.1 Overview

    10.15.2 Product Overview

    10.15.3 Financials

    10.15.4 Key Developments

    10.15.5 SWOT Analysis

    10.16 Pfizer

    10.16.1 Overview

    10.16.2 Product Overview

    10.16.3 Financials

    10.16.4 Key Developments

    10.16.5 SWOT Analysis

    10.17 Takeda Pharmaceuticals

    10.17.1 Overview

    10.17.2 Product Overview

    10.17.3 Financials

    10.17.4 Key Developments

    10.17.5 SWOT Analysis

    Chapter 11 MRFR Conclusion

    11.1 Key Findings

    11.1.1 From CEO’s Viewpoint

    11.1.2 Unmet Needs of the Market

    11.2 Key Companies to Watch

    11.3 Predictions for the Multiple Myeloma Treatment Market

    Chapter 12. Appendix


    LIST OF TABLES

    Table 1 Global Multiple Myeloma Treatment Market Synopsis, 2020–2027

    Table 2 Global Multiple Myeloma Treatment Market Estimates and Forecast, 2020–2027 (USD Million)

    Table 3 Global Multiple Myeloma Treatment Market, by Region, 2020–2027 (USD Million)

    Table 4 Global Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)

    Table 5 Global Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 6 North America: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)

    Table 7 North America: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 8 US: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)

    Table 9 US: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 10 Canada: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)

    Table 11 Canada: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 12 South America: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)

    Table 13 South America: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 14 Europe: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)

    Table 15 Europe: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 16 Western Europe: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)

    Table 17 Western Europe: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 18 Eastern Europe: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)

    Table 19 Eastern Europe: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 20 Asia-Pacific: Multiple Myeloma Treatment Market, by Treatment, 2020–2027 (USD Million)

    Table 21 Asia-Pacific: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)

    Table 22 Middle East & Africa: Multiple Myeloma Treatment Market, by Treatment, 2020-2027 (USD Million)

    Table 23 Middle East & Africa: Multiple Myeloma Treatment Market, by End-User, 2020–2027 (USD Million)



    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Multiple Myeloma Treatment Market

    Figure 3 Segmentation Market Dynamics for Global Multiple Myeloma Treatment Market

    Figure 4 Global Multiple Myeloma Treatment Market Share, by Treatment, 2020

    Figure 5 Global Multiple Myeloma Treatment Market Share, by End-User, 2020

    Figure 6 Global Multiple Myeloma Treatment Market Share, by Region, 2020

    Figure 7 North America: Multiple Myeloma Treatment Market Share, by Country, 2020

    Figure 8 Europe: Multiple Myeloma Treatment Market Share, by Country, 2020

    Figure 9 Asia-Pacific: Multiple Myeloma Treatment Market Share, by Country, 2020

    Figure 10 Middle East & Africa: Multiple Myeloma Treatment Market Share, by Country, 2020

    Figure 11 Global Multiple Myeloma Treatment Market: Company Share Analysis, 2020 (%)

    Figure 12 Celgene Corporation: Key Financials

    Figure 13 Celgene Corporation: Segmental Revenue

    Figure 14 Celgene Corporation: Geographical Revenue

    Figure 15 Janssen Biotech, Inc.: Key Financials

    Figure 16 Janssen Biotech, Inc.: Segmental Revenue

    Figure 17 Janssen Biotech, Inc.: Geographical Revenue

    Figure 18 Bristol-Myers Squibb Company: Key Financials

    Figure 19 Bristol-Myers Squibb Company: Segmental Revenue

    Figure 20 Bristol-Myers Squibb Company: Geographical Revenue

    Figure 21 Novartis AG: Key Financials

    Figure 22 Novartis AG: Segmental Revenue

    Figure 23 Novartis AG: Geographical Revenue

    Figure 24 Millennium Pharmaceuticals: Key Financials

    Figure 25 Millennium Pharmaceuticals: Segmental Revenue

    Figure 26 Millennium Pharmaceuticals. Geographical Revenue

    Figure 27 Amgen, Inc: Key Financials

    Figure 28 Amgen, Inc: Segmental Revenue

    Figure 29 Amgen, Inc: Geographical Revenue

    Figure 30 Genzyme Corporation: Key Financials

    Figure 31 Genzyme Corporation: Segmental Revenue

    Figure 32 Genzyme Corporation: Geographical Revenue

    Figure 33 Juno Therapeutics: Key Financials

    Figure 34 Juno Therapeutics: Segmental Revenue

    Figure 35 Juno Therapeutics: Geographical Revenue

    Figure 36 Johnson & Johnson: Key Financials

    Figure 37 Johnson & Johnson: Segmental Revenue

    Figure 38 Johnson & Johnson: Geographical Revenue

    Figure 39 F. Hoffmann-La Roche Ltd: Key Financials

    Figure 40 F. Hoffmann-La Roche Ltd: Segmental Revenue

    Figure 41 F. Hoffmann-La Roche Ltd: Geographical Revenue

    Figure 42 GlaxoSmithKline plc: Key Financials

    Figure 43 GlaxoSmithKline plc: Segmental Revenue

    Figure 44 GlaxoSmithKline plc: Geographical Revenue

    Figure 45 AbbVie Inc: Key Financials

    Figure 46 AbbVie Inc: Segmental Revenue

    Figure 47 AbbVie Inc: Geographical Revenue

    Figure 48 Innate Pharma SA: Key Financials

    Figure 49 Innate Pharma SA: Segmental Revenue

    Figure 50 Innate Pharma SA: Geographical Revenue

    Figure 51 Celldex Therapeutics, Inc: Key Financials

    Figure 52 Celldex Therapeutics, Inc: Segmental Revenue

    Figure 53 Celldex Therapeutics, Inc: Geographical Revenue

    Figure 54 BrainScope Company, Inc, Inc: Key Financials

    Figure 55 BrainScope Company, Inc, Inc: Segmental Revenue

    Figure 56 BrainScope Company, Inc, Inc: Geographical Revenue

    Figure 57 Pfizer, Inc: Key Financials

    Figure 58 Pfizer, Inc: Segmental Revenue

    Figure 59 Pfizer, Inc: Geographical Revenue

    Figure 60 Takeda Pharmaceuticals, Inc: Key Financials

    Figure 61 Takeda Pharmaceuticals, Inc: Segmental Revenue

    Figure 62 Takeda Pharmaceuticals, Inc: Geographical Revenue

    Figure 63 Onyx Pharmaceuticals: Key Financials

    Figure 64 Onyx Pharmaceuticals: Segmental Revenue

    Figure 65 Onyx Pharmaceuticals: Geographical Revenue

    Figure 66 Silver Creek Pharmaceuticals Inc: Key Financials

    Figure 67 Silver Creek Pharmaceuticals Inc: Segmental Revenue

    Figure 68 Silver Creek Pharmaceuticals Inc: Geographical Revenue

    Figure 69 Stemedica Cell Technologies Inc: Key Financials

    Figure 70 Stemedica Cell Technologies Inc: Segmental Revenue

    Figure 71 Stemedica Cell Technologies Inc: Geographical Revenue

    Figure 72 Banayan Biomarkers Inc: Key Financials

    Figure 73 Banayan Biomarkers Inc: Segmental Revenue

    Figure 74 Banayan Biomarkers Inc: Geographical Revenue

    Figure 75 Vasopharm GmbH: Key Financials

    Figure 76 Vasopharm GmbH: Segmental Revenue

    Figure 77 Vasopharm GmbH: Geographical Revenue